Aprea Therapeutics Stock Jumps After Eprenetapopt Combo Data Presentation At ESMO

Aprea Therapeutics Inc APRE presented data at the European Society of Medical Oncology (ESMO) Congress 2021 from its Phase 1/2 trial in advanced solid tumors.
The trial is evaluating the safety and efficacy of eprenetapopt in combination with pembrolizumab.
Related: Aprea Therapeutics Stock Drops On FDA Clinical Hold On Eprenetapopt Myeloid Malignancy Trials.
As of the July 31 data cutoff, 33 patients were enrolled, and 31 had initiated treatment.
In the bladder/urothelial cohort, one patient with locally advanced TP53 mutant high-grade transitional cell bladder cancer achieved complete remission (CR).
In the NSCLC cohort, two patients with TP53 mutant squamous NSCLC had reductions in target lesions of 26.7% and 8.2%, respectively, from baseline.
Read Next: Aprea Therapeutics Stock Drops After FDA Clinical Hold On Another Blood Cancer Study.
Price Action: APRE stock is up 3.09% at $5.00 during the premarket session on the last check Tuesday.